164.08

0.02% 0.03

Axsome Therapeutics Inc (AXSM)

Overview News Price History Option Chain Financials Why AXSM Down? Discussions Forecast

Axsome Therapeutics Inc stock is traded at $164.08, with a volume of 425.70K. It is up +0.02% in the last 24 hours and down -11.57% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Previous Close:

$164.05

Open:

$164.02

24h Volume:

425.70K

Relative Volume:

0.66

Market Cap:

$8.39B

Revenue:

$638.50M

Net Income/Loss:

$-183.17M

P/E Ratio:

-44.41

EPS:

-3.6943

Net Cash Flow:

$-93.89M

1W Performance:

-0.09%

1M Performance:

-11.57%

6M Performance:

+31.89%

1Y Performance:

+30.67%

1-Day Range:

$163.22

$166.09

1-Week Range:

$160.10

$168.00

52-Week Range:

$86.99

$191.50

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name

Axsome Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(212) 332-3241

Address

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Employee

925

Twitter

Next Earnings Date

2026-02-23

Latest SEC Filings

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AXSM Axsome Therapeutics Inc	164.08	8.39B	638.50M	-183.17M	-93.89M	-3.6943
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-01-25	Initiated	B. Riley Securities	Buy
Sep-03-25	Resumed	Wells Fargo	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Initiated	Oppenheimer	Outperform
Apr-07-25	Initiated	Jefferies	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-31-24	Reiterated	Mizuho	Outperform
Sep-03-24	Initiated	Wells Fargo	Overweight
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy
Jul-22-24	Initiated	Needham	Buy
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-06-24	Initiated	UBS	Buy
Jan-25-24	Initiated	RBC Capital Mkts	Outperform
Dec-13-23	Initiated	Citigroup	Buy
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral
Jan-05-23	Initiated	Piper Sandler	Neutral
Nov-01-22	Initiated	Loop Capital	Buy
Sep-07-22	Resumed	Mizuho	Buy
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-10-21	Initiated	Berenberg	Buy
Jan-08-21	Initiated	Jefferies	Buy
Dec-16-20	Initiated	Mizuho	Buy
Sep-29-20	Initiated	BofA Securities	Underperform
Sep-10-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Reiterated	H.C. Wainwright	Buy
Apr-14-20	Initiated	Cowen	Outperform
Dec-30-19	Reiterated	H.C. Wainwright	Buy
Dec-17-19	Reiterated	H.C. Wainwright	Buy
Dec-16-19	Reiterated	Guggenheim	Buy
Oct-16-19	Initiated	Guggenheim	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-28-19	Initiated	SunTrust	Buy
May-23-19	Reiterated	H.C. Wainwright	Buy
Apr-08-19	Initiated	SVB Leerink	Outperform
Mar-15-19	Reiterated	H.C. Wainwright	Buy
Oct-03-16	Resumed	Brean Capital	Buy
Dec-15-15	Initiated	Cantor Fitzgerald	Buy
Dec-14-15	Initiated	Ladenburg Thalmann	Buy

View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

Mar 04, 2026